Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 3 3Phase 2/3 2Phase 1/2 2Phase NA 1Phase 1 1

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Breast 1

Conditions

Neoplasm Metastasis 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

pembrolizumab 79Cyclophosphamide 55Specimen Handling 54Carboplatin 50fludarabine 44Nivolumab 42Magnetic Resonance Spectroscopy 42Biopsy 38Gemcitabine 37Bevacizumab 34Dexamethasone 31venetoclax 27Paclitaxel 26Injections 25Docetaxel 25atezolizumab 24Pemetrexed 24Cisplatin 24Ipilimumab 23Capecitabine 21Temozolomide 19Fulvestrant 19abemaciclib 18Rituximab 18Oxaliplatin 18Lenalidomide 18Cetuximab 18Azacitidine 18Vincristine 15Fluorouracil 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × bicalutamide × 90 days × Clear all
NCT05095207 2026-04-13

Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer

Icahn School of Medicine at Mount Sinai

Phase 1/2 Recruiting
42 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT06222593 2026-04-01

Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination With Sunitinib in Patients With TKIs-resistant RCC

State University of New York at Buffalo

Phase 1/2 Recruiting
28 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡